Abstract：Objective：To study the mechanism of Jinzhen Eye Drops in treating dry eye disease based on network pharmacology and molecular docking. Methods：All chemical constituents and targets of action of Jinzhen Eye Drops were screened out by using Traditional Chinese Medicine Systems Pharmacology (TCMID) and Traditional Chinese Medicine Integrated Database (TCMID). Targets related to dry eye disease were screened through Human Genes (GeneCards) and Online Mendelian Inheritance in Man (OMIM). The potential targets of Jinzhen Eye Drops in treating dry eye disease were obtained by using RGUI software to draw Venn diagram； the protein-protein interaction network was constructed by using STRING database and Cytoscape software. GO function and KEGG enrichment analysis were performed via ClusterProfiler of RGUI software. AutoDockTools and Vina software were used for molecular docking of key targets and active constituents， and Pymol software was used to draw docking results. Results： A total of 34 main active constituents and 221 common targets of medicine and disease were found in Jinzhen Eye Drops. Important target genes for the treatment of dry eye disease include AKT1， TP53， HSP90AA1， mitogen-activated protein kinase 3 (MAPK3)， tumor necrosis factor (TNF)， interleukin-6 (IL-6) and epidermal growth factor receptor (EGFR). It mainly acted on PI3K-Akt， TNF， interleukin-17 (IL-17)， MAPK， and epidermal growth factor receptor signaling pathways. The results of molecular docking showed that the main active constituents of Jinzhen Eye Drops had strong binding activity with the core targets. Conclusion： Jinzhen Eye Drops may act on AKT1，TP53，HSP90AA1，MAPK3，TNF，IL-6，EGFR and other targets through PI3K-Akt， TNF， IL-17， MAPK， and EGFR signaling pathways， which plays the role of antiinflammatory， antioxidant， antibacterial， alleviating the imbalance of the microenvironment on the ocular surface and nerve paresthesia，and plays the role of treating dry eye disease.